Cancer Vaccines: What Could They Mean for You?

The phrase “cancer vaccine” can sound almost contradictory. Vaccines are usually associated with preventing infectious diseases before they occur, whereas cancer is not an infection and is actually made from our own cells.

Did you know, though, that vaccines can also be used as treatments? Therapeutic cancer vaccines are designed to teach the immune system to recognize cancer cells that are already present and attack them more effectively [1].

This is different from vaccines such as those against human papillomavirus (HPV) and hepatitis B virus (HBV). Those vaccines prevent infections that can later cause cancers, and therefore reduce cancer risk indirectly [2]. Moderna and Merck’s experimental therapy, known as mRNA-4157/V940 and now called intismeran autogene, is an individualized therapeutic vaccine created from the genetic features of each patient’s own tumor.

In August 2026, they reached an important milestone that broke the news. Moderna and Merck announced that a large Phase III melanoma trial had met its main efficacy goals. While this is not yet a universal ‘vaccine against cancer,’ it marks a significant step toward therapies tailored to the unique biology of an individual patient’s tumor.

So what does that actually mean? We are here to break it down: how this vaccine works, how it differs from the vaccines we already know, and what it could mean for the future of cancer treatment.

Cancer creates an unusual challenge for the immune system. Viruses and bacteria are clearly foreign. Cancer cells, by contrast, originate from our own tissues, so many of their proteins look normal to the immune system.

But as cancer develops, its DNA accumulates mutations. Some mutations alter proteins in ways that create molecular features known as neoantigens, new antigens that can be present on cancer cells but absent from healthy cells. In principle, these provide the immune system with something distinctive to attack [3].

The difficulty is that two people with the same type of cancer can have very different mutations. That is where personalization becomes important.

Intismeran, the new drug, is designed individually for each patient. It uses messenger RNA, or mRNA, the temporary molecule cells normally use to carry instructions for making proteins. In this case, the mRNA encodes as many as 34 neoantigens selected from that patient’s tumor [4].

The aim is to generate or expand T cells, immune cells capable of identifying and killing cells displaying those abnormal targets.

The vaccine is being developed together with pembrolizumab (Keytruda), an immunotherapy that helps remove the “brakes” cancer can place on the immune system. In simple terms, the vaccine teaches immune cells what to look for, while pembrolizumab helps them stay active enough to attack it [12]. The combination is particularly logical after surgery. Even when all visible melanoma has been removed, microscopic cancer cells may remain and later cause recurrence. A trained immune response could, in principle, help find and eliminate those residual cells.

The strongest mature evidence so far comes from KEYNOTE-942, a randomized Phase IIb trial involving 157 patients whose high-risk stage IIIB-IV melanoma had been completely removed surgically [4].

Patients received either pembrolizumab alone or pembrolizumab plus the personalized mRNA therapy. In the initial peer-reviewed analysis, 78.6% of patients receiving the combination were alive without recurrence at 18 months, compared with 62.2% receiving pembrolizumab alone. The statistical analysis corresponded to a 44% relative reduction in the risk of recurrence or death during the follow-up period [4].

Longer follow-up has strengthened the finding. In June 2026, five-year results were published. The combination continued to show a 49% relative reduction in the risk of recurrence or death compared with pembrolizumab alone and a 59% reduction in the risk of distant metastasis or death [5].

The latest development came on 19 August 2026. Moderna and Merck announced positive topline results from INTerpath-001, a Phase III trial involving 1137 patients with completely resected stage IIB-IV cutaneous melanoma. At a planned interim analysis, the combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant-metastasis-free survival compared with pembrolizumab alone [6,7].

This is an important result because Phase III studies are designed to test therapies in substantially larger populations. However, caution is still warranted. The companies have not yet released the numerical size of the Phase III benefit, and the results have not yet been presented in full or peer reviewed. Overall-survival follow-up is continuing. The companies have said they plan to discuss regulatory submissions with health authorities [6].

Importantly, the program is expanding beyond melanoma. Phase III trials are evaluating treatment in several settings of non-small cell lung cancer [8-10]. Earlier-stage studies are investigating the approach in renal cell carcinoma, bladder cancer and other tumors [14,15]. These trials test an important question that melanoma alone cannot answer: will the approach work broadly across cancers with very different biology?

The underlying idea is closely related, but the clinical goal is very different.

Both approaches use mRNA as temporary biological instructions. The mRNA is read by cells to produce a protein target that can be shown to the immune system. It does not need to enter the cell nucleus, and does not alter DNA and is eventually broken down [13].

With a COVID-19 mRNA vaccine, however, researchers already know the target: a viral protein shared by the virus circulating through the population. Essentially the same vaccine can therefore be manufactured for millions of people.

A personalized cancer vaccine has no single universal target. Instead, scientists must sequence an individual's tumor, identify its mutations, predict useful neoantigens and manufacture a new mRNA sequence for that person.

There is also an important difference in purpose. COVID vaccines are principally preventive: they prepare the immune system before or around exposure to a pathogen. Intismeran is primarily being developed as a cancer treatment, included after surgery to reduce the risk that an existing cancer will return.

Personalization does not guarantee that the immune system will defeat a tumor.

First, not every mutation makes a good neoantigen. Computational prediction remains imperfect, and some tumors contain relatively few useful mutations. A selected neoantigen may also fail to trigger a strong T-cell response [3,11].

Tumors can also evolve. Cancer cells that lose a targeted antigen may escape immune recognition. Other tumors create highly immunosuppressive environments in which activated T cells struggle to function [11].

Producing an individualized treatment also requires tumor tissue, genomic sequencing, complex computational analysis, quality-controlled manufacturing and careful tracking so that each product reaches the correct patient. That introduces time, cost and infrastructure requirements that do not exist to the same degree with an off-the-shelf drug. If personalized cancer vaccines become approved treatments, ensuring access beyond major specialist centers will be an important challenge.

Finally, melanoma is particularly responsive to immune-based treatments and often carries many mutations. Success there does not guarantee the same result in cancers with fewer neoantigens or more difficult immune environments. Determining which tumors, and which patients, benefit most will require the results of the wider clinical program.

The idea of a “cancer vaccine” can easily be misunderstood. Intismeran is not a universal injection that prevents healthy people from developing cancer, and it should not yet be described as a cure.

What is emerging is more specific, and perhaps more scientifically interesting.

The five-year Phase IIb melanoma data show that this strategy can produce a durable improvement in recurrence-related outcomes when combined with an immunosuppressant, pembrolizumab [5]. The positive Phase III announcement in August 2026 provides a much stronger test of the concept, although the full results are still needed before its magnitude and clinical implications can be judged [6].

If those results hold up, and if similar benefits can eventually be demonstrated in other cancers, the major advance may not be a single “vaccine against cancer.” It may be the development of a platform capable of turning the genetic fingerprint of an individual tumor into a set of instructions for the immune system.

Whether that promise translates into routine cancer care will now depend on the next set of questions: How durable is the protection? Does it improve overall survival? Which cancers respond? How quickly and affordably can individualized vaccines be manufactured? Can patients access them at scale?

Whether personalized mRNA vaccines ultimately become a major part of cancer care will depend not only on the success of current clinical trials, but also on the discoveries that come next. Supporting fundamental research today is what makes the next generation of therapies possible tomorrow.